These two British drugs behemoths are similar businesses that both pay bigdividends, and theyve mostlytended to move in lockstep. However, in recent monthsGlaxoSmithKline (LSE: GSK) has sported a much higher and hence more potentially more attractive yield than AstraZeneca (LSE: AZN). So whats up? Owain Bennallack investigates
To find out the strategies to adopt if you want tobecome one of the growing number of surprise UK millionaires, read this FREE Motley Fool report:’7 Simple Steps For Seeking Serious Wealth‘ while it remains available!
Owain Bennallackowns shares in GSK and AZN. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
